Bad news for Novartis, good for GlaxoSmithKline: Sandoz' Advair copy stiff-armed at FDA
admin 8th February 2018 Uncategorised 0Novartis CEO Vas Narasimhan last month said the company’s Advair generic—specifically its approval this year—was one of his top three worries for 2018. That worry just grew. In a blow to Novartis and a boon for GlaxoSmithKline, the FDA rejected the generic.
More: Bad news for Novartis, good for GlaxoSmithKline: Sandoz' Advair copy stiff-armed at FDA
Source: fierce